Table 1.
Characteristics of patients with herpes zoster, pain scores, and salivary varicella-zoster virus (VZV) DNA burden during antiviral treatment.
| Patient (age in years/sex) | Underlying disease | Zoster sitea | Days of pain before antiviral treatment, | Days of rash before antiviral treatment | Day 1 (start of treatment) | Day 8 | Day 15 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Pain | VZVb | Pain | VZVb | Pain | VZVb | |||||
| 1 (64/F) | None | V1 | 2 | 1 | 3 | 1.4 × 107 | ND | ND | 0 | 0 |
| 2 (52/M) | Stomach cancer | V1 | 4 | 2 | 3 | 3.2 × 104 | 0 | 0 | 0 | 0 |
| 3 (44/M) | None | V1 | 18 | 12 | 7 | 1.0 × 105 | 3 | 9.3 × 103 | 0 | 0 |
| 4 (48/F) | None | V1 | 1 | 1 | 2 | 1.8 × 105 | 1 | 1.8 × 103 | 1 | 1.8 × 103 |
| 5 (59/F) | None | V1 | 1 | 1 | 1 | 6.3 × 102 | 0 | 0 | 0 | 0 |
| 6 (62/M) | Cancer | V1 | 14 | 7 | 5 | 2.5 × 104 | 5 | 6.8 × 104 | 7 | 4.7 × 104 |
| 7 (41/M) | None | V1 | 6 | 2 | 6 | 1.0 × 103 | 0 | 6.3 × 102 | 0 | 0 |
| 8 (82/F) | Infected finger | V1 | 7 | 2 | 4 | 5.5 × 103 | 2 | 2.2 × 103 | 0 | 0 |
| 9 (75/M) | Hypertension | C2 | 3 | 1 | 1 | 7.2 × 104 | 0 | 3.4 × 104 | 2 | 1.3 × 103 |
| 10 (65/M) | Hypertension, hypothyroidism | C2 | 7 | 3 | 8 | 5.0 × 105 | 5 | 4.9 × 102 | 3 | 0 |
| 11 (79/M) | None | C2–C3 | 6 | 2 | 6 | 6.5 × 103 | ND | ND | ND | ND |
| 12 (49/F) | None | C3 | 1 | 1 | 7 | 1.4 × 107 | 2 | 7.5 × 102 | 0 | 0 |
| 13 (40/M) | Colon cancer | C3 | 3 | 7 | 3 | 1.2 × 106 | 2 | 3.8 × 103 | 2 | 3.5 × 102 |
| 14 (53/F) | Hepatitis | C3 | 6 | 1 | 6 | 8.0 × 100 | ND | ND | 0 | 0 |
| 15 (44/F) | None | C3 | 3 | 1 | 7 | 5.8 × 105 | 2 | 0 | 0 | 0 |
| 16 (48/M) | Malignant brain tumor | C3 | 3 | 1 | 2 | 4.5 × 101 | 4 | 3.0 × 102 | 6 | 1.0 × 105 |
| 17 (63/M) | Back surgery | C3–C4 | 14 | 10 | 4 | 6.5 × 104 | 0 | 0 | 0 | 0 |
| 18 (26/F) | None | C4 | 21 | 3 | 6 | 8.2 × 104 | 2 | 0 | 0 | 0 |
| 19 (26/F) | None | C4 | 12 | 5 | 4 | 4.5 × 104 | ND | ND | ND | ND |
| 20 (47/F) | Cancer | T1 | 2 | 1 | 1 | 8.0 × 101 | 0 | 0 | 0 | 0 |
| 21 (58/F) | Lumbar disk disease | T2 | 14 | 4 | 5 | 2.0 × 104 | 2 | 2.1 × 102 | 0 | 0 |
| 22 (53/F) | Asthma, anemia | T2–T3 | 13 | 3 | 6 | 6.6 × 103 | ND | ND | ND | ND |
| 23 (66/F) | None | T3 | 5 | 1 | 3 | 6.9 × 101 | 0 | 0 | 0 | 0 |
| 24 (51/M) | None | T3–T4 | 7 | 6 | 2 | 4.2 × 101 | 0 | 0 | 0 | 0 |
| 25 (75/M) | None | T3–T4 | 4 | 2 | 2 | 4.3 × 102 | 0 | 0 | 0 | ND |
| 26 (39/F) | None | T4 | 5 | 3 | 4 | 2.3 × 101 | 0 | 0 | 0 | 0 |
| 27 (48/M) | None | T4–T5 | 3 | 2 | 5 | 8.8 × 104 | 0 | 3.1 × 103 | 0 | 0 |
| 28 (30/F) | None | T5 | 4 | 3 | 6 | 4.4 × 101 | ND | ND | 0 | 0 |
| 29 (56/F) | Hyperlipidemia, kidney stone, diabetes | T5 | 5 | 3 | 3 | 6.5 × 101 | 0 | 0 | 0 | 0 |
| 30 (60/M) | None | T5 | 8 | 7 | 2 | 9.0 × 100 | 0 | ND | 0 | 0 |
| 31 (65/M) | None | T5 | 3 | 1 | 8 | 1.9 × 104 | 6 | 1.7 × 105 | 0 | 0 |
| 32 (59/M) | None | T5 | 3 | 2 | 3 | 1.6 × 101 | 0 | 0 | 0 | 0 |
| 33 (62/M) | None | T5 | 12 | 5 | 1 | 1.6 × 102 | 4 | 0 | 2 | 0 |
| 34 (62/M) | None | T5–T6 | 3 | 2 | 5 | 1.2 × 102 | 6 | 4.8 × 102 | 6 | 4.5 × 104 |
| 35 (58/F) | None | T6 | 4 | 2 | 2 | 1.3 × 102 | ND | ND | ND | ND |
| 36 (43/F) | None | T6 | 5 | 3 | 4 | 2.1 × 101 | 0 | 0 | ND | ND |
| 37 (61/M) | Hypertension, chronic back pain | T6 | 6 | 3 | 4 | 5.8 × 102 | 0 | 0 | 0 | 0 |
| 38 (40/M) | None | T6 | 2 | 1 | 2 | 1.9 × 103 | 0 | 0 | 0 | 0 |
| 39 (39/M) | None | T6 | 6 | 5 | 5 | 2.7 × 107 | 2 | 3.5 × 105 | 0 | 0 |
| 40 (35/F) | Hypertension | T6–T7 | 9 | 4 | 8 | 7.6 × 103 | 3 | 6.1 × 103 | 0 | 0 |
| 41 (59/F) | None | T7 | 3 | 2 | 2 | 2.7 × 101 | 0 | 0 | 1 | 0 |
| 42 (23/F) | None | T7–T8 | 6 | 6 | 3 | 2.6 × 104 | 0 | ND | 0 | 0 |
| 43 (50/M) | None | T8 | 5 | 3 | 6 | 1.5 × 103 | 3 | 0 | 0 | 0 |
| 44 (35/M) | Heart disease | T8 | 14 | 3 | 2 | 6.5 × 101 | 0 | 0 | 0 | 0 |
| 45 (72/F) | None | T11 | 5 | 2 | 2 | 2.2 × 102 | 3 | 2.6 × 103 | 0 | 0 |
| 46 (69/F) | None | T11 | 3 | 2 | 3 | 3.5 × 101 | ND | ND | 0 | 0 |
| 47 (65/F) | None | T12 | 2 | 1 | 6 | 5.7 × 103 | 0 | 0 | 0 | 0 |
| 48 (21/F) | None | T12 | 3 | 0 | 9 | 5.5 × 103 | ND | ND | ND | ND |
| 49 (51/F) | None | L1 | 2 | 1 | 2 | 2.9 × 101 | 0 | 0 | 0 | 0 |
| 50 (58/F) | None | L2–L3 | 4 | 2 | 3 | 4.3 × 101 | 0 | 0 | 2 | 0 |
| 51 (72/M) | None | L3 | 1 | 1 | 3 | 1.5 × 102 | ND | ND | 1 | 0 |
| 52 (67/F) | None | L3 | 5 | 1 | 3 | 1.4 × 102 | 0 | 0 | 0 | 0 |
| 53 (44/F) | None | L4–L5 | 21 | 3 | 4 | 4.5 × 104 | 0 | 1.1 × 102 | 0 | 0 |
| 54 (74/M) | None | L5 | 2 | 1 | 2 | 1.4 × 102 | ND | ND | 0 | 0 |
NOTE. ND, not determined because of failure of patient to return to the clinic for follow-up of pain/salivary VZV DNA determinations.
a
Site of zoster: C, cervical; L, lumbar; T, thoracic; V1, ophthalmic division of trigeminal nerve.
b
VZV DNA copies/mL of saliva.